Everolimus + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Tuberous Sclerosis
Conditions
Tuberous Sclerosis, Subependymal Giant Cell Astrocytoma
Trial Timeline
Aug 1, 2009 → Oct 1, 2014
NCT ID
NCT00789828About Everolimus + Placebo
Everolimus + Placebo is a phase 3 stage product being developed by Novartis for Tuberous Sclerosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00789828. Target conditions include Tuberous Sclerosis, Subependymal Giant Cell Astrocytoma.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01529554 | Phase 1/2 | Completed |
| NCT01524783 | Phase 3 | Completed |
| NCT01133678 | Phase 2 | Terminated |
| NCT00789828 | Phase 3 | Completed |
Competing Products
13 competing products in Tuberous Sclerosis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Everolimus (RAD001) + Everolimus Placebo | Novartis | Phase 3 | 77 |
| RAD001 | Novartis | Phase 1/2 | 41 |
| Placebo + Everolimus (RAD001) | Novartis | Phase 2 | 52 |
| RAD001 + Placebo | Novartis | Phase 2 | 52 |
| RAD001 + Placebo + Antiepileptic drug (1 to 3 only) + open label RAD001 (only used for post-extension phase) | Novartis | Phase 3 | 77 |
| Everolimus | Novartis | Phase 1/2 | 41 |
| everolimus (RAD001) | Novartis | Phase 1/2 | 41 |
| everolimus | Novartis | Phase 3 | 77 |
| sirolimus | Pfizer | Phase 2 | 51 |
| GWP42003-P | Jazz Pharmaceuticals | Phase 3 | 74 |
| GWP42003-P | Jazz Pharmaceuticals | Phase 3 | 74 |
| GWP42003-P + Placebo | Jazz Pharmaceuticals | Phase 3 | 74 |
| Cannabidiol Oral Solution [Epidiolex] | Jazz Pharmaceuticals | Approved | 82 |